Clinical Trial Update: Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4) [Phase 1]

View source ↗

Summary

Phase 1b/2 open-label dose-escalation study of ND-L02-s0201 in patients with moderate to extensive hepatic fibrosis (METAVIR F3-4) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Fibrosis

Drugs mentioned

• ND-L02-s0201

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4) | Phase 1 | Status: COMPLETED